ReviewInternational journal of hypertension2013
Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases.
Review in International journal of hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- Evaluation of Salusin-α and Salusin-β Levels in Human Saliva Samples from Patients with Gingivitis and Periodontitis: A Cross-Sectional Study.Biomedicines · 2026Article
- The effect of danshen ligustrazine injection as adjuvant therapy on serum levels of salusins, catestatin, MMP-2, MMP-9, and TIMP-1 in patients with primary hypertension.BMC complementary medicine and therapies · 2025Article
- The relationship between serum salusins levels and atherosclerosis, endothelial dysfunction and cardiac morphology in autosomal dominant polycystic kidney disease.International urology and nephrology · 2025Article
- Article
- Tear and blood salusin-α, and -β, copeptin, and asprosin in patients with glaucoma and ocular hypertension.Arquivos brasileiros de oftalmologia · 2025Article
- Evaluation of serum salusin-α and β levels in patients with obstructive sleep apnea.Biomarkers in medicine · 2024Article
- Serum salusin-β levels in patients with systemic lupus erythematosus.Clinical rheumatology · 2023Article
- The Clinical Significance of Salusins in Systemic Sclerosis-A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2023Article
- The role of serum salusin alpha and beta levels and atherosclerotic risk factors in idiopathic sudden hearing loss pathogenesis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Article
- Current Knowledge of Selected Cardiovascular Biomarkers in Pediatrics: Kidney Injury Molecule-1, Salusin-α and -β, Uromodulin, and Adropin.Children (Basel, Switzerland) · 2022Review
- Serum salusin-α and salusin-β levels in patients with psoriatic arthritis.Reumatologia · 2022Article
- Salusin‑β participates in high glucose‑induced HK‑2 cell ferroptosis in aMolecular medicine reports · 2021Article
- Relationship between Serum Salusin Beta Levels and Coronary Artery Ectasia.Acta Cardiologica Sinica · 2021Article
- Anti‑inflammatory effect of salusin‑β knockdown on LPS‑activated alveolar macrophages via NF‑κB inhibition and HO‑1 activation.Molecular medicine reports · 2021Article
- A TOR2A Gene Product: Salusin-β Contributes to Attenuated Vasodilatation of Spontaneously Hypertensive Rats.Cardiovascular drugs and therapy · 2021Article
- Improvement of Vascular Function by Knockdown of Salusin-β in Hypertensive Rats via Nitric Oxide and Reactive Oxygen Species Signaling Pathway.Frontiers in physiology · 2021Article
- Salusin-The Journal of international medical research · 2020Article
- Article
- Salusin beta, atherosclerosis, and coronary slow flow.Anatolian journal of cardiology · 2020Article
- Effects of Two Types of Moderate- and High-Intensity Interval Training on Serum Salusin-α and Salusin-β Levels and Lipid Profile in Women with Overweight/Obesity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human salusin- α and salusin- β are related peptides produced from prosalusin. Bolus injection of salusin- β into rats induces more profound hypotension and bradycardia than salusin- α . Central administration of salusin- β increases blood pressure via release of norepinephrine and arginine-vasopressin. Circulating levels of salusin- α and salusin- β are lower in patients with essential hypertension. Salusin- β exerts more potent mitogenic effects on human vascular smooth muscle cells (VSMCs) and fibroblasts than salusin- α . Salusin- β accelerates inflammatory responses in human endothelial cells and monocyte-endothelial adhesion. Human macrophage foam cell formation is stimulated by salusin- β but suppressed by salusin- α . Chronic salusin- β infusion into apolipoprotein E-deficient mice enhances atherosclerotic lesions; salusin- α infusion reduces lesions. Salusin- β is expressed in proliferative neointimal lesions of porcine coronary arteries after stenting. Salusin- α and salusin- β immunoreactivity have been detected in human coronary atherosclerotic plaques, with dominance of salusin- β in macrophage foam cells, VSMCs, and fibroblasts. Circulating salusin- β levels increase and salusin- α levels decrease in patients with coronary artery disease. These findings suggest that salusin- β and salusin- α may contribute to proatherogenesis and antiatherogenesis, respectively. Increased salusin- β and/or decreased salusin- α levels in circulating blood and vascular tissue are closely linked with atherosclerosis. Salusin- α and salusin- β could be candidate biomarkers and therapeutic targets for atherosclerotic cardiovascular diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.